Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

New appointment adds clinical expertise to Board

Leeds, 1 June, 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that it has appointed Professor Shervanthi Homer - Vanniasinkam as a Non- Executive Director with immediate effect.

Professor Homer-Vanniasinkam is a respected Consultant Vascular Surgeon who holds a number of appointments at medical and academic institutions across the country, and is regularly invited to lecture at prestigious establishments across the world. She was recently appointed to the First Chair of Engineering and Surgery at University College London, and currently holds positions which include Clinical Sub - Dean, University of Leeds Medical School and Professor of Surgery University of Warwick Medical School and University Hospitals Coventry and Warwickshire. Professor Homer-Vanniasinkam has been acting as a clinical advisor to the Group for a number of years and has extensive experience of medical research, development and innovation.

John Samuel, Chairman of Tissue Regenix Group commented: "We welcome the appointment of Shervanthi as a Non- Executive Director, having supported Tissue Regenix in an advisory role for a number of years. With a strong commercially - focussed Board we feel it imperative to match this with clinical expertise as the Group continues to grow and bring dCELL® to the market. The appointment of Shervanthi at this time highlights the continued momentum of Tissue Regenix as we expand further into the US marketplace and bring human tissue applications to Europe." 

Further Information:

Full Name: Shervanthi Homer- Vanniasinkam

Age: 58

Other Corporate Board positions: N/A

Present Appointments:

Consultant Vascular Surgeon, Leeds Vascular Institute, Leeds General Infirmary

Clinical Sub-Dean, University of Leeds Medical School & Director of EXSEL@Leeds

Professor of Surgery (Founding), University of Warwick Medical School &

University Hospitals Coventry and Warwickshire

​Professor of Engineering and Surgery, University College London

There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.